Abstract
Background and study aim : Chronic Hepatitis C virus (HCV) infection is typically characterized by slowly progressive hepatic fibrosis. However, it is recognized that some patients do not progress while others rapidly develop significant fibrosis. Immune response mechanism in the control of viral replication and persistence in HCV induced liver disease has been well documented. Solute carrier 11a1 (SLC11A1) plays an immunomodulatory role in influencing macrophage activation status and the T helper 1/T helper 2 biases. It modulates the susceptibility to infectious/autoimmune diseases. The study aimed to: Analyze the possible involvement of polymorphism in the promoter regions of the SLC11A1 gene in the susceptibility for chronic hepatitis C infection and the progression of fibrosis in these patients. Patients and methods: This study included 138 subjects. They were classified into 2 groups: Group I that included 69 matched apparently healthy persons and Group II that included 69 chronic hepatitis C patients (Child A) and was divided into 2 subgroups: Group (IIA): It included 35 chronic hepatitis C patients without fibrosis and Group (IIB): It included 34 chronic hepatitis C patients with fibrosis. All individuals were subjected to: Full history taking, complete physical and clinical examination, abdominal ultrasound, fibroscan, routine laboratory investigations, viral markers and determination of SLC11A1 promoter gene polymorphism. Results: The present study demonstrated that no statistically significant difference was observed in the distribution of SLC11A1 genotype frequencies among patient and control groups, suggested absence of association between the presence of the polymorphism and the prevalence of disease. Moreover, chronic hepatitis C patients who had SLC11A1 2/2 genotype were significantly at decreased risk to develop fibrosis 0.2 times than those who had 3/3 genotype [OR:0.2, CI:(0.52-0.79)] suggesting that the 2/2 genotype is associated with an decreased susceptibility to develop fibrosis. Conclusion and recommendations: SLC11A1 gene promoter polymorphism could influence fibrosis progression in chronic hepatitis C in that the homozygous genotype 2/2 exerts a protective effect against cirrhosis development. Gene therapy may have an important role in the treatment and prognosis of HCV infection which need further studies.
Highlights
Hepatitis C virus (HCV) is recognized as a major cause of chronic liver disease [1]
Chronic hepatitis C virus infection is typically characterized by slowly progressive hepatic fibrosis
Our results showed that chronic hepatitis C patients who had Solute carrier 11a1 (SLC11A1) 2/2 genotype were significantly at decreased risk to develop fibrosis 0.2 times than those who had 3/3 genotype
Summary
Hepatitis C virus (HCV) is recognized as a major cause of chronic liver disease [1]. Patients with hepatitis C may have chronic hepatitis for as long as 40 years before progressing to cirrhosis [2].Once cirrhosis occurs, hepatocellular carcinoma (HCC) develops in 1-4% of these patients per year. Hepatitis C virus (HCV) is recognized as a major cause of chronic liver disease [1]. Patients with hepatitis C may have chronic hepatitis for as long as 40 years before progressing to cirrhosis [2]. Hepatocellular carcinoma (HCC) develops in 1-4% of these patients per year. Egypt has a very high prevalence of HCV and a high morbidity and mortality from chronic liver disease, cirrhosis, and HCC [3]. Chronic Hepatitis C virus (HCV) infection is typically characterized by slowly progressive hepatic fibrosis. The study aimed to: Analyze the possible involvement of polymorphism in the promoter regions of the SLC11A1 gene in the susceptibility for chronic hepatitis C infection and the progression of fibrosis in these patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Afro-Egyptian Journal of Infectious and Endemic Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
